Studies have shown that the anti-CEMIP monoclonal antibody (anti-CEMIP), ipriflavone, and paclitaxel (PTX) combined with the latest nanosphere-targeted drug delivery technology can make CEMIP as a therapeutic target to inhibit inflammation or tumor development (9, 10). Here, CEMIP is linked to neoplasm.